Live Breaking News & Updates on Andrew Carlsen

Stay updated with breaking news from Andrew carlsen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Transactions with shares and linked securities in Genmab

Transactions with shares and linked securities in Genmab
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Andrew Carlsen , Marisol Peron , Asia Pacific , Company Announcement , Exchange Commission , Global Communications Corporate Affairs , Market Abuse , Implementing Regulation , North America , Senior Vice President , Global Communications , Vice President , Annual Report , Y Shaped Genmab , Jacobsens Vej ,

Genmab A/S: Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma

Preliminary analysis of data from the EPCORE NHL-2 study demonstrates patients with previously untreated follicular lymphoma (FL) who received epcoritamab in combination with rituximab-lenalidomide ....

United States , Judith Klimovsky , Hematol Hemoter , Asia Pacific , Joshua Brody , David Freundel , Andrew Carlsen , Drug Administration , Lymphoma Research Foundation , Leukemia Lymphoma Society , Genmab Us Inc , American Society Of Clinical Oncology , Global Communications Corporate Affairs , Data From The Observational National Lymphocare Study , Exchange Commission , Abbvie Biotechnology Ltd , Clinical Oncology , Annual Meeting , Mount Sinai Hess Center , Priority Review , Biologics License Application , Follicular Lymphoma , Medication Guide , North America , Media Release , Annual Report ,

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)

Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previously treated PD-L1-positive metastatic. ....

United States , Asia Pacific , Andrew Carlsen , Fosun Pharma , David Freundel , Judith Klimovsky , Globenewswire Inc , American Cancer Society , American Society Of Clinical Oncology , Exchange Commission , Roche Group , Clinical Oncology , Annual Meeting , Executive Vice President , Chief Development Officer , Chief Medical Officer , Media Release , Annual Report , Y Shaped Genmab , New Technologies , Private Securities Litigation Reform Act , Non Small Cell ,

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in

Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with. ....

United States , Judith Klimovsky , Fosun Pharma , David Freundel , Andrew Carlsen , Asia Pacific , Exchange Commission , American Society Of Clinical Oncology , American Cancer Society , Roche Group , Clinical Oncology , Annual Meeting , Executive Vice President , Chief Development Officer , Chief Medical Officer , Non Small Cell Lung Cancer , North America , Media Release , Annual Report , Y Shaped Genmab , New Technologies , Private Securities Litigation Reform Act , American Cancer , Non Small Cell Lung , Lung Cancer , Non Small Cell ,

Genmab A/S : Investigational Acasunlimab (DuoBody® PD L1x4 1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non small Cell Lung Cancer (mNSCLC)

English

. ....

United States , Andrew Carlsen , Acasunlimab Duobody , Asia Pacific , Fosun Pharma , David Freundel , Roche Group , Global Communications Corporate Affairs , Exchange Commission , American Society Of Clinical Oncology , American Cancer Society , Clinical Oncology , Annual Meeting , Non Small Cell Lung Cancer , North America , Media Release , Annual Report , Y Shaped Genmab , New Technologies , Private Securities Litigation Reform Act , Senior Director , Global Communications , Vice President , American Cancer , Non Small Cell Lung , Accessed May ,